雷贝拉唑与莫沙必利联合用于反流性食管炎患者治疗的临床效果观察

Clinical Observation of the Combined Use of Rabeprazole and Mosapride in the Treatment of Patients with Reflux Esophagitis

目的探究在反流性食管炎患者中采用雷贝拉唑与莫沙必利联合治疗的临床效果。方法纳入上高县人民医院2021年10月至2023年10月收治的76例反流性食管炎患者,按随机数字表法分两组,各38例。对照组使用雷贝拉唑,观察组使用雷贝拉唑联合莫沙必利治疗。比较两组临床疗效、胃肠激素、炎症反应、24 h食管pH值监测结果及不良反应。结果观察组治疗总有效率(94.74%)较对照组(78.95%)高(P<0.05);两组治疗前胃肠激素、炎症反应、24 h食管pH值监测结果差异无统计学意义(P>0.05),治疗后观察组胃泌素、胃动素均较对照组高,血管活性肠肽较对照组低,白细胞介素(IL)-17、IL-6、IL-23、肿瘤坏死因子-α水平均较对照组低,pH值<4反流次数、反流持续时间≥5 min次数较对照组少,最长反流持续时间较对照组短(P<0.05)。两组不良反应对比差异无统计学意义(P>0.05)。结论雷贝拉唑联合莫沙必利治疗反流性食管炎效果显著,可减轻炎症反应,调节胃肠激素,减少反流次数,缩短反流时间,且安全可靠。

Objective To explore the clinical effect of rabeprazole combined with mosapride in the treatment of reflux esophagitis(RE).Methods A total of 76 RE patients admitted to Shanggao County People's Hospital from October 2021 to October 2023 were enrolled and randomly divided into two groups,38 cases in each group.The control group was treated with rabeprazole,and the observation group were treated rabeprazole combined with mosapride.The clinical efficacy,gastrointestinal hormones,inflammatory reaction,24 h esophageal pH monitoring,and adverse reactions were compared between the two groups.Results The total effective rate of the observation group(94.74%)was higher than that of the control group(78.95%)(P<0.05).There were no statistically significant difference in the gastrointestinal hormones,inflammatory reaction and 24 h esophageal pH monitoring of the two groups before treatment(P>0.05),after treatment,the gastrinb and motilin in the observation group were higher than those in the control group,vasoactive intestinal peptide was lower than that in the control group;interleukin(IL)-17、IL-6、IL-23、tumor necrosis factor-αin the observation group were lower than those in the control group;the number of reflux times,reflux duration≥5 min and the longest reflux duration in the observation group were less than those in the control group(P<0.05).There were no statistically significant difference in the adverse reactions of the two groups(P>0.05).Conclusion Rabeprazole combined with mosapride in the treatment of RE patients,which can reduce the inflammatory reaction,regulate gastrointestinal hormones,reduce the number of reflux,shorten the reflux time,and is safe and reliable.